Freselestat

DB03925ExperimentalSmall molecule

Investigated for use/treatment in chronic obstructive pulmonary disease (COPD).

Mechanism: ONO-6818 inhibits neutrophil elastase activity, reducing interleukin 8 production and the formation of the complement membrane attack complex. Consequently, neutrophil elastase levels are reduced during stimulated extracorporeal circulation.
Curator reviewed
Primary indication: Investigated for use/treatment in chronic obstructive pulmonary disease (COPD).Curator reviewed
Formula / weight: C₂₃H₃₀N₆O₄ · 454.5221 g/mol (avg)
Code names: CP-955 · ONO-6818 · ONO-PO 736

Resolves to

Compound

Structure

InChIKeyHMPQTEPEMQZWQH-QZTJIDSGSA-NSMILESCC(C)[C@@H](NC(=O)CN1C(=O)C(N)=CN=C1C1=CC=CC=C1)[C@@H](O)C1=NN=C(O1)C(C)(C)C

Targets

What you can answer from here — as of August 31, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Freselestat, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.